据路透社报道,2024年11月11日,医药股德纳维制药公司(DVAX.US)股价盘中大涨6.53%,最高达到13.84美元,成交量显著增加。
这次股价上涨主要受到该公司宣布与高盛银行合作推出1亿美元的加速股票回购计划的影响。根据消息,德纳维制药预计将最初回购约610万股,占交易的80%,最终结算将于明年第一季度完成。此次回购计划是该公司早前宣布2亿美元回购计划的一部分。
德纳维制药是一家总部位于加州的生物制药公司,专注于利用先天性免疫反应和适应性免疫反应。其主打产品是HEPLISAV-B乙肝疫苗,同时公司还在开发多种癌症治疗疫苗。上一财季该公司实现营收8063万美元,净利润1759万美元。目前公司市值约18亿美元,流通股1.315亿股,机构普遍给予"买入"评级。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.